Drug intelligence / Profile preview

verrucarin A

Development stage
Preclinical
Modality
Small Molecules
Administration
Intravenous, Intraperitoneal
01

Overview

Verrucarin A is a potent Type D macrocyclic trichothecene mycotoxin primarily produced by fungi such as *Albifimbria verrucaria* (formerly *Myrothecium verrucaria*). It acts as a potent inhibitor of protein synthesis by binding to the A-site of the 60S ribosomal subunit in eukaryotes, thereby triggering a ribotoxic stress response. Beyond its role as a toxin, verrucarin A has been investigated for its significant anticancer properties, demonstrating the ability to induce apoptosis and inhibit prosurvival signaling pathways such as Akt/NF-κB/mTOR. It also functions as an inhibitor of steroid receptor coactivators (SRC-1, SRC-2, and SRC-3). Due to its high systemic toxicity, recent research has focused on targeted delivery systems, including antibody-directed extracellular vesicles (EVs) and folate-receptor-targeted conjugates, to treat glioblastoma, triple-negative breast cancer, neuroendocrine tumors, and inflammatory disorders. Additionally, it exhibits antifungal, antimalarial, and nematicidal activities.

Other names
Mu-1Mu1Mu 1
02

Targets

28S rRNA (28S ribosomal RNA)NCOA3 (Nuclear receptor coactivator 3)60S (Eukaryotic 60S ribosomal subunit)NCOA1 (Nuclear receptor coactivator 1)NCOA2 (Nuclear receptor coactivator 2)

Beyond the preview

Go deeper on verrucarin A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on verrucarin A.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call